|
|
Blood, Vol. 113, Issue 19, 4505-4511, May 7, 2009
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group
Blood Gaidzik et al.
113: 4505
Supplemental materials for: Gaidzik et al
Treatment plans including dosages of cytotoxic drugs of protocols AML HD93, AML HD98-A, and AMLSG 07-04
Protocols AML HD93 and AML HD98-A studies (age 18 to 60 years): induction therapy consisted of one course of ICE (12 mg/m2 idarubicin, d 1, 3, 5; cytarabine 100 mg/m2, continuously d 1–7; 100 mg/m2 etoposide, d 1–3) followed by a second course of ICE started between days 21 and 28 in patients achieving a complete or partial remission, or by a course of a high-dose cytarabine-based regimen in patients with ICE-refractory disease. First consolidation therapy consisted of a course of HAM (3 g/m2 cytarabine every 12 hours, d 1–3; 12 mg/m2 mitoxantrone, d 2+3). Second consolidation therapy for patients with normal cytogenetics differed between the AML HD93 and AML HD98-A trials. In the AML HD93 trial, patients 16 to 54 years of age were assigned to receive a course according to the S-HAM protocol (3 g/m2 cytarabine every 12 hours, d 1, 2, 8 +9; 10 mg/m2 mitoxantrone, d 3, 4, 10+11), whereas patients above the age of 54 years received the less-intensive HAM regimen. In the AML HD98-A trial, patients were randomized either to a second course of HAM or myeloablative conditioning followed by an autologous stem cell transplantation (SCT). In both trials a genetic randomisation was performed in that patients with an HLA-matched family donor were assigned to an allogeneic SCT. Patients enrolled in the AMLSG 07-04 trial (age 18 to 60 years) were randomized based on a two-by-two factorial design for all-trans retinoic acid (ATRA) and valproic acid (VPA) into four arms: i) ICE; ii) ICE + ATRA (45 mg/m2; d 6–8, 15 mg/m2; d 9–21); iii) ICE + VPA (mid-fast saturation with VPA i.v. 400 mg bid. d 1+2, followed by serum level adapted p.o. treatment with retard formulation 4 times a day with a target serum level of 50 to 150 mg/l); iv). ICE + VPA + ATRA. Analogous to the AML HD93 and AML HD98-A studies, patients received a double induction therapy. Consolidation therapy consisted of three cycles of high-dose cytarabine (3 g/m2 bid. for 3 days). Again, a genetic randomisation was performed in that patients with an HLA-matched family donor were assigned to an allogeneic SCT. Members of the German-Austrian Study Group AMLSG:
Daniel Oruzio M.D. Klinikum Augsburg, Augsburg, Germany
Ingo Schmidt-Wolf M.D. Universitätsklinikum Bonn, Bonn, Germany
Bernd Hertenstein M.D. Klinikum Bremen-Mitte, Bremen, Germany
Ulrich Germing M.D. Universitätsklinikum Düsseldorf, Düsseldorf, Germany
Wolfgang Heit M.D. Krankenhaus Essen-Werden, Essen, Germany
Dieter Hoelzer M.D. Universitätsklinikum Frankfurt, Frankfurt, Germany
Hans G. Derigs M.D. Städtische Kliniken Frankfurt am Main-Höchst, Frankfurt, Germany
Michael Lübbert, M.D. Universitätsklinikum Freiburg, Freiburg, Germany
Andrea Distelrath M.D. Klinikum Fulda, Fulda, Germany
Hans Pralle M.D. Universitätsklinikum Gießen, Gießen, Germany
Volker Rund M.D. Wilhelm-Anton-Hospital, Goch, Germany
Detlef Haase M.D. Universitätsklinikum Göttingen, Göttingen, Germany
Walter Fiedler, Universität Hamburg, Hamburg, Germany
Hans Salwender M.D. Allgemeines Krankenhaus Altona, Hamburg, Germany
Andrea Sendler M.D. Klinikum Hanau, Hanau, Germany
Hartmut Kirchner M.D. Krankenhaus Siloah, Hannover, Germany
Manfred Hensel M.D. Universitätsklinikum Heidelberg, Heidelberg, Germany
Uwe Martens, SLK-Kliniken GmbH Heilbronn, Heilbronn, Germany
Michael Pfreundschuh M.D. Universitätsklinikum Homburg/Saar, Homburg, Germany
Günther Gastl M.D. Universitätsklinikum Innsbruck, Innsbruck, Austria
Martin Bentz M.D. Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
Michael Kneba M.D. Universitätsklinikum Kiel, Kiel, Germany
Stefan Kremers M.D. Caritas-Krankenhaus Lebach, Lehbach, Germany
Andreas Petzer M.D. Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria
Gerhard Heil M.D, Klinikum Lüdenscheid, Lüdenscheid, Germany
Thomas Fischer M.D. Universitätsklinikum Mainz, Mainz, Germany
Katharina Götze M.D. Technische Universität München, München, Germany
Christine Waterhouse M.D. Klinikum München-Schwabing, München, Germany
Francesco del Valle M.D. Klinikum Oldenburg, Oldenburg, Germany
Axel Matzdorff M.D. Caritas-Klinik St. Theresia, Saarbrücken, Germany
Richard Greil M.D. Salzburger Landeskliniken, Salzburg, Austria
Hans-Günther Mergenthaler M.D. Klinikum Stuttgart, Stuttgart, Germany
Else Heidemann M.D. Diakonie-Klinikum Stuttgart. Stuttgart, Germany
Heinz Kirchen M.D. Krankenhaus der Barmherzigen Brüder, Trier, Germany
Lothar Kanz M.D. Universitätsklinikum Tübingen, Tübingen, Germany
Wolfgang Brugger M.D. Klinikum Villingen-Schwenningen, Villingen-Schwenningen, Germany
Elisabeth Koller M.D. Hanuschkrankenhaus, Vienna, Austria
Aruna Raghavachar M.D. Helios Klinikum Wuppertal, Wuppertal, Germany.
Files in this Data Supplement:
|
|
